AstraZeneca, a multinational pharmaceutical company, said on the 12th (local time) that it had not found any evidence that the novel coronavirus infection (Corona 19) vaccine developed with Oxford University in the UK increases the risk of developing blood clots.
AstraZeneca spokesman said, “The analysis of more than 10 million data showed no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in a particular age group, gender, manufacturing unit, or country,” the AFP news agency said.
“In fact, the size of this type of outbreak observed among vaccinators is much smaller than expected in the general population,” the spokesman added.
Recently, there have been reports of blood clots being vaccinated by AstraZeneca in some European countries, but the response methods are different.
In Austria, the production unit was’ABV5300′, and in Italy,’ABV2856′, a case of blood clotting after AstraZeneca vaccination was reported, and the production unit vaccination was temporarily stopped.
Bulgaria, Denmark, Norway and Iceland temporarily stopped vaccination against AstraZeneca as a precautionary measure in case of an unforeseen event.
Unlike these countries, the World Health Organization (WHO) and the European Medicines Agency (EMA) have argued that there are no problems with the safety of the AstraZeneca vaccine.
The UK, Sweden, France, Spain, and the Netherlands are continuing the AstraZeneca vaccination in line with the recommendations of the WHO and EMA.
The French Agency for Health and Product Safety (ANSM) announced that there was only one case in France that reported blood clotting after receiving the AstraZeneca vaccine, and that a causal relationship with vaccination was not confirmed.
The Paulerrich Institute (PEI), which is responsible for vaccine approval in Germany, also found no indication that AstraZeneca vaccination caused blood clot-related diseases.
/yunhap news
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution